News

H.C. Wainwright Adjusts Ekso Bionics Target Amid Growth Prospects

H.C. Wainwright Adjusts Ekso Bionics Target Amid Growth Prospects

H.C. Wainwright Adjusts Price Target for Ekso Bionics

Recently, H.C. Wainwright revised its projections regarding Ekso Bionics (NASDAQ: EKSO), a company well-known for its innovative exoskeleton technologies. The investment firm reduced its price target from $10.00 to $9.00, while still maintaining a Buy rating due to the company's potential for growth. This adjustment comes after Ekso Bionics released its third-quarter financial results, which were below market expectations.

Financial Overview and Adjusted Projections

In its latest quarterly report, Ekso Bionics generated revenues of $4.1 million, falling short of analyst predictions that were around $5.5 million. Moreover, the company reported a net loss of $0.10 per share, which, although lesser than the $0.11 estimated loss, reflects ongoing challenges. In response to these figures, H.C. Wainwright has chosen to update its financial outlook for the firm.

The revised projections for 2024 now forecast total revenue of $17.9 million, a decrease from the earlier estimate of $21.1 million. Correspondingly, the anticipated net loss has changed to $0.48 per share. The price target reduction largely results from the recent financial data presented by Ekso Bionics and persistent difficulties related to reimbursement processes for its EKSO Indego product line.

Market Reactions and Future Potentials

The newly settled price target reflects H.C. Wainwright's recalibrated outlook and acknowledges the current financial trends influencing Ekso Bionics. Although the target has been decreased, the maintained Buy rating suggests a sustained confidence in the company's ability to rebound and grow.

Highlights from Recent Sales Performance

In the wake of these adjustments, it's important to note that Ekso Bionics previously reported record quarterly sales of $5 million in its second quarter of 2024, notwithstanding a slight overall revenue decline. The company successfully sold 37 units of their EksoHealth devices during this time and achieved favorable payment rulings from the Centers for Medicare & Medicaid Services (CMS) for the Ekso Indego Personal device. This reimbursement ruling, which is pegged at a significant rate, marks a pivotal milestone for both the company and spinal cord injury patients benefiting from the technology.

Expansion Strategy for EksoHealth

Moreover, Ekso Bionics has rolled out the EksoHealth Personal Program in the U.S. Designed to help patients obtain personal exoskeletons, this program is expected to interact with Medicare Advantage plans and various commercial insurance providers in the near future. Although the company experienced a net loss of $5.8 million during the first half of 2024, effective measures in controlling operational costs suggest a focus on expansion.

Growth Potential and Financial Insights

The company is optimistic that the Ikego Personal program will have a major influence on revenues starting in 2025, as it seeks to broaden the availability of exoskeleton technology and capture a larger share of the market.

As of the latest twelve-month report ending the second quarter of 2024, Ekso Bionics posted revenue growth of 15.63%, totaling $18.16 million. This suggests positive momentum, even amidst adjustments in forecasts. Though the company continues to operate at a net loss, experts project a potential rebound this year, which could alleviate some concerns raised by its recent quarterly statistics.

Current Financial Standing of Ekso Bionics

It’s worth mentioning that despite these growth signs, Ekso Bionics has not achieved profitability recently, reporting an operating income margin of -65.92%. This statistic coincides with H.C. Wainwright's current projections for the company’s net loss in 2024. Ekso Bionics is navigating a complex financial landscape but remains committed to stabilizing its performance.

Frequently Asked Questions

What recent changes did H.C. Wainwright make regarding Ekso Bionics?

H.C. Wainwright has lowered its price target for Ekso Bionics from $10.00 to $9.00 while maintaining a Buy rating.

What were the key financial results for Ekso Bionics last quarter?

Ekso Bionics reported revenues of $4.1 million and a net loss of $0.10 per share in its latest quarterly results.

How is Ekso Bionics planning to expand its market reach?

The company has launched the EksoHealth Personal Program in the U.S. and aims to collaborate with Medicare Advantage plans and commercial insurers in the near future.

What does the future look like for Ekso Bionics?

Ekso Bionics anticipates that the Indego Personal program will significantly enhance revenue from 2025 onward, despite current financial losses.

Is Ekso Bionics profitable?

No, as of the latest reports, Ekso Bionics has shown a net loss with an operating income margin of -65.92%.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 56

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 0

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 85

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 34

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 16

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 76

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 33

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 54

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 15

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Join Class Action Against Vestis Corporation

Updated Category News Views 240

Important Notice for Investors in Vestis Corporation Levi & Korsinsky, LLP is reaching out to those who have invested in Vestis Corporation (NYSE: VSTS) regarding a significant class action securities lawsuit. This initiative is intended for individuals who believe they faced losses as a consequence of the alleged securities fraud involving the company. Understanding the...

Continue Reading
Wegovy's Impact on MASH Care: Insights into Physician Adoption

Updated Category News Views 168

Wegovy's Revolutionary Role in MASH Treatment Wegovy, known in the medical community as semaglutide 2.4mg, has recently garnered approval as a treatment for metabolic dysfunction-associated steatohepatitis (MASH). This development is viewed as a crucial advancement for a condition that affects a substantial patient population. With significant unmet needs, the...

Continue Reading
Opportunity for Orthofix Investors to Join Class Action Lawsuit

Updated Category News Views 248

Class Action Lawsuit Opportunity for Orthofix Investors Investors in Orthofix Medical Inc. have been alerted to a significant opportunity. A class action lawsuit is underway against Orthofix, involving allegations against current and former officers for violations of federal securities laws. If you are among those who encountered substantial losses due to the handling of...

Continue Reading
Meta Strengthens AI Infrastructure with Rivos Acquisition

Updated Category News Views 252

Meta Platforms Aims for AI Dominance Meta Platforms (NASDAQ:META) is making significant strides in the realm of artificial intelligence, channeling resources into massive chip investments and potential acquisitions to bolster its infrastructure. As one of the giants in U.S. technology, Meta is set on further establishing its presence in AI technology with a commitment of...

Continue Reading
Renovating Older Homes? Structural Insight is Key

Updated Category News Views 28

Unearthing the Bones of Older Homes It ain't rocket science to realize that before you swing a sledgehammer in an old house, you’d better know what you’re dealing with. The walls might look like just a bunch of paint and plaster, but underneath, they tell stories older than most of us. It's all laid out in this HelloNation chat with Jason Marks from Ward Construction....

Continue Reading